参考文献/References:
［1］ Llovet JM， Di Bisceglie AM， Bruix JA， et al. Design and endpoints of clinical trials in hepatocellular carcinoma［J］. J Natl Cancer Inst， 2008， 100： 698- 711.
［2］ Celsa C， Cabibbo G， Enea M， et al. Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?［J］. Liver Int， 2021， 41： 1105- 1116.
［3］ Wang H， Li B， Wang Y， et al. Time to untreatable progression is an appropriate surrogate endpoint for overall survival in patients with hepatocellular carcinoma after transarterial chemoembo- lization［J］. J Cancer Res Ther， 2020， 16： 301- 308.
［4］ Llovet JM， Villanueva A， Marrero JA， et al. Trial design and endpoints in hepatocellular carcinoma： AASLD consensus conference［J］. Hepatology， 2021， 73（Suppl 1)：158- 191.
［5］ Finn RS. Progression- free survival： starting point or endpoint in advanced HCC trial design?［J］. J Hepatol， 2019， 70： 1062- 1064.
［6］ Raoul JL， Gilabert M， Piana G. How to define transarterial chemoembolization failure or refractoriness： a European perspective［J］. Liver Cancer， 2014， 3： 119- 124.
［7］ 张 雯，周永杰，颜志平． 再论精细TACE［J］． 介入放射学杂志， 2021， 30：971- 975．
［8］ Kim HY， Park JW， Joo J， et al. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepa-tocellular carcinoma［J］. J Gastroenterol Hepatol， 2012， 27： 1051- 1056.
［9］ Kudo M， Han G， Finn RS， et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma： a randomized phase Ⅲ trial［J］. Hepatology， 2014， 60： 1697- 1707.
［10］ Lencioni R， Llovet JM， Han G， et al. Sorafenib or placebo plus TACE with doxorubicin- eluting beads for intermediate stage HCC： the SPACE trial［J］. J Hepatol， 2016， 64： 1090- 1098.
［11］ 贾中芝，顾晓诚，蒋国民． 门静脉癌栓分型对肝细胞性肝癌治疗方法的选择及患者预后的影响［J］． 介入放射学杂志， 2017，26：944- 947．
［12］ 李 果，吴黎雳，宦宏波，等． 肝细胞癌肝外转移对患者生存预后的影响［J］． 中华解剖与临床杂志， 2014， 19：307- 309．
［13］ Bruix J， Reig M， Rimola J， et al. Clinical decision making and research in hepatocellular carcinoma： pivotal role of imaging techniques［J］. Hepatology， 2011， 54： 2238- 2244.
［14］ Reig M， Forner A， Rimola J， et al. BCLC strategy for prognosis prediction and treatment recommendation： the 2022 update［J］. J Hepatol， 2022， 76： 681- 693.
［15］ Choi JW， Kim HC， Lee JH， et al. Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus［J］. Eur Radiol， 2017， 27： 1448- 1458.
［16］ Xiang X， Lau WY， Wu ZY， et al. Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus： a multicenter study［J］. Eur J Surg Oncol， 2019， 45： 1460- 1467.
［17］ Lee IC， Huo T， Huang YH， et al. Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma： a propensity score matching analysis［J］. Hepatol Int， 2012， 6： 753- 762.
［18］ Zhong BY， Wang WS， Zhang S， et al. Re- evaluating transarterial chemoembolization failure/refractoriness： a survey by Chinese college of interventionalists［J］. J Clin Transl Hepatol， 2021， 9： 521- 527.
［19］ Edeline J， Boucher E， Rolland Y， et al. Comparison of tumor response by response evaluation criteria in solid tumors（RECIST) and modified RECIST in patients treated with sorafenib for hepa-tocellular carcinoma［J］. Cancer， 2012， 118： 147- 156.
［20］ Ronot M， Bouattour M， Wassermann J， et al. Alternative Response Criteria（Choi，European association for the study of the liver，and modified response evaluation criteria in solid tumors［RECIST］)versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib［J］. Oncologist， 2014， 19： 394- 402.
［21］ Takada J， Hidaka H， Nakazawa T， et al. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma［J］. BMC Res Notes， 2015， 8： 609.
［22］ Gillmore R， Stuart S， Kirkwood A， et al. EASL and mRECIST responses are independent prognostic factors for survival in hepa-tocellular cancer patients treated with transarterial embolization［J］. J Hepatol， 2011， 55： 1309- 1316.
［23］ Kim BK， Kim SU， Kim KA， et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma［J］. J Hepatol， 2015， 62： 1304- 1310.
［24］ Georgiades C， Geschwind JF， Harrison N， et al. Lack of response after initial chemoembolization for hepatocellular carcinoma： does it predict failure of subsequent treatment?［J］. Radiology， 2012， 265： 115- 123.
［25］ Terzi E， Golfieri R， Piscaglia F， et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”［J］. J Hepatol， 2012， 57： 1258- 1267.
［26］ Chen S， Peng Z， Zhang Y， et al. Lack of response to transarterial chemoembolization for intermediate- stage hepatocellular carcinoma： abandon or repeat?［J］. Radiology， 2021， 298： 680- 692.
［27］ Zhang W， Chen L， Cao Y， et al. Efficacy of drug- eluting beads transarterial chemoembolization plus apatinib compared with conventional transarterial chemoembolization plus apatinib in the treatment of unresectable hepatocellular carcinoma［J］. Cancer Manag Res， 2021， 13： 5391- 5402.
［28］ Sznol M. Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents： useful endpoint or hype?［J］. Curr Opin Investig Drugs， 2010， 11： 1340- 1341.
［29］ Brown DB， Gould JE， Gervais DA， et al. Transcatheter therapy for hepatic malignancy： standardization of terminology and reporting criteria［J］. J Vasc Interv Radiol， 2009， 20： S425- S434.
［30］ Guiu B， Deschamps F， Boulin M， et al. Serum gamma- glutamyl- transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma： external validation［J］. Cardiovasc Intervent Radiol， 2012， 35： 1102- 1108.
［31］ Hidaka H， Izumi N， Aramaki T， et al. Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase Ⅲ trial（ORIENTAL)［J］. Med Oncol， 2019， 36： 52.
［32］ Kudo M， Izumi N， Kokudo N， et al. Management of hepatocellular carcinoma in Japan： consensus- based clinical practice guidelines proposed by the Japan Society of Hepatology（JSH) 2010 updated version［J］. Dig Dis， 2011， 29： 339- 364.
［33］ Kudo M， Matsui O， Izumi N， et al. Transarterial chemoembolization failure/refractoriness： JSH- LCSGJ criteria 2014 update［J］. Oncology， 2014， 87（Suppl 1)： 22- 31.
［34］ Labeur T， Takkenberg RB， Klümpen HJ， et al. Reason of discontinuation after transarterial chemoembolization influences survival in patients with hepatocellular carcinoma［J］. Cardiovasc Intervent Radiol， 2019， 42： 230- 238.
［35］ Arizumi T， Minami T， Chishina H， et al. Time to transcatheter arterial chemoembolization refractoriness in patients with hepato-cellular carcinoma in Kinki criteria stages B1 and B2［J］. Dig Dis， 2017， 35： 589- 597.
［36］ Kudo M. Proposal of primary endpoints for TACE combination trials with systemic therapy： lessons learned from 5 negative trials and the positive TACTICS trial［J］. Liver Cancer， 2018， 7： 225- 234.
［37］ 张 申，张 磊，仲斌演，等． “TACE抵抗/失败”——需要全面认识［J］． 介入放射学杂志， 2020， 29：743- 747．
［38］ Arizumi T， Ueshima K， Iwanishi M， et al. The overall survival of patients with hepatocellular carcinoma correlates with the newly defined time to progression after transarterial chemo-embolization［J］. Liver Cancer， 2017， 6： 227- 235.
［39］ Izumoto H， Hiraoka A， Ishimaru Y， et al. Validation of newly proposed time to transarterial chemoembolization progression in intermediate- stage hepatocellular carcinoma cases［J］. Oncology， 2017， 93（Suppl 1)： 120- 126.
相似文献/References:
[1]王海军,郝欣,李建辉,等. 肝癌经导管动脉化疗栓塞术后并发肝包膜下巨大脓肿一例[J].介入放射学杂志,2012,(03):255.
,,et al.Ｈｕｇｅ ｈｅｐａｔｉｃ ｓｕｂｃａｐｓｕｌａｒ ａｂｓｃｅｓｓ ｏｃｃｕｒｒｅｄ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｆｏｒ ｔｈｅ ｔｒｅａｔｍｅｎｔ ｏｆ ｌｉｖｅｒ ｃａｎｃｅｒ： ｒｅｐｏｒｔ ｏｆ ｏｎｅ ｃａｓｅ [J].journal interventional radiology,2012,(07):255.